Pharma Firm Outlines Busy Trial Calendar and Development Updates
Syntara Limited (PMXSF) leadership has detailed an ambitious clinical development roadmap for 2026 during a recent investor presentation, forecasting a steady stream of trial updates throughout the year.
2026 Clinical Milestones
CEO Gary Phillips characterized the coming year as exceptionally active compared to industry peers, with multiple pipeline assets expected to generate frequent progress reports. “Our clinical pipeline positions us to deliver near-constant news flow through 2026,” Phillips stated during the webinar. “We’re initiating this year by providing shareholders greater transparency about our anticipated developments.”
Leadership Perspectives
Phillips was joined by Non-Executive Director Hashan De Silva, who represents major shareholder KPRX. De Silva brings both governance oversight and investor perspective to Syntara’s strategic direction, having tracked the company’s evolution from earlier stages.
“Having Hashan’s dual perspective as board member and significant stakeholder strengthens our approach,” Phillips noted, highlighting De Silva’s decade-long involvement with the company.
Strategic Priorities
The presentation emphasized Syntara’s focus on delivering concrete clinical data across its development programs. While specific trial details weren’t disclosed, officials confirmed multiple readouts and study initiations are scheduled across therapeutic areas throughout 2026.
Company leadership fielded shareholder questions regarding development timelines and milestone expectations, though no new financial guidance was provided during the session.
